丁苯酞注射液联合阿替普酶溶栓治疗急性脑梗死患者的效果

Effects of Butylphthalide injection combined with Alteplase thrombolytic therapy in patients with acute cerebral infarction

目的:观察丁苯酞注射液联合阿替普酶溶栓治疗急性脑梗死患者的效果。方法:选取92例急性脑梗死患者为研究对象,按随机数字表法将其分为对照组与观察组各46例。对照组采用阿替普酶静脉溶栓治疗,观察组在对照组基础上联合丁苯酞注射液治疗,比较两组治疗前后神经缺损程度[美国国立卫生研究院卒中量表(NIHSS)]评分、脑神经功能指标[脑利钠肽(BNP)、神经元特异性烯醇化酶(NSE)、S100β蛋白]水平、血清炎性因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]水平和不良反应发生率。结果:治疗后,观察组NIHSS评分低于对照组,差异有统计学意义(P<0.05);治疗后,观察组BNP、NSE、S100β蛋白水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组IL-6、CRP、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:丁苯酞注射液联合阿替普酶溶栓治疗急性脑梗死患者可降低NIHSS评分、脑神经功能指标水平和血清炎性因子水平,其效果优于单纯阿替普酶静脉溶栓治疗。

Objective: To observe effects of Butylphthalide injection combined with Alteplase thrombolytic therapy in patients with acute cerebral infarction. Methods: 92 patients with acute cerebral infarction were selected as the research objects, and were divided into control group and observation group according to the random number table method, 46 cases in each group. The control group was treated with Alteplase intravenous thrombolytic therapy, while the observation group was treated with Butylphthalide injection based on the treatment of that of the control group. The degree of neurological deficit [National Institutes of Health Stroke Scale(NIHSS)], the cranial nerve function index levels [brain natriuretic peptide(BNP), neuron-specific enolase(NSE), S100β protein], the serum inflammatory factor levels [interleukin-6(IL-6), C-reactive protein(CRP), tumor necrosis factor-α(TNF-α)] and incidence of adverse reactions were compared between the two groups before and after the treatment. Results: After the treatment, the NIHSS score of the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05).After the treatment, the levels of BNP, NSE and S100β in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). After the treatment, the levels of IL-6, CRP and TNF-α in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). However, there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusions: Butylphthalide injection combined with Alteplase thrombolytic therapy in the treatment of the patients with acute cerebral infarction can reduce the NIHSS score, the levels of cranial nerve function indexes and the levels of serum inflammatory factors. Moreover, it is superior to single Alteplase thrombolytic therapy.